Blackstone is raising a new life sciences fund, targeting at least $5B after initial $1.6B closing. Blackstone Life Sciences ...

Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP-1 drugs while facing potential legal challenges.

Sev­er­al months in­to a mul­ti­year quest to “rig­or­ous­ly pri­or­i­tize” its pipeline, Take­da is cut­ting a hand­ful of pro­grams. The com­pa­ny re­vealed the changes on Thurs­day … ...

API maker Bright Green plans $3.5B US facilities; EU launches biotech hub; Q4 earnings from Thermo Fisher, Sartorius, Danaher; Piramal reports growth; Upperton completes UK site ...

Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart disease called pulmonary hypertension in heart failure with preserved ejection ...

Define Ventures identifies about 20 health tech startups, including Innovaccer, Hinge Health & Devoted Health that are poised for exits with $500M-$800M revenue.

Take­da CEO Christophe We­ber will step down next June af­ter more than 10 years lead­ing the Japan­ese drug­mak­er. Julie ...

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...

Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...

Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale and plans €5B share buyback.